



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
CASE NO. 02-896-A

In Re Application of:)	
Gould, et al)	
)	Examiner:
Serial No.: 10/678,927)	
)	Group Art Unit: 1614
Filed: October 3, 2003)	
)	
Title: Method for Treating)	
Patients with Massive)	
Blood Loss)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached:
2.
 - a. Transmittal Letter;
 - b. Form PTO 1449 and 52 cited references;
 - c. Postcard.
3. No Fee is required.
4. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490.

Respectfully submitted,

McDONNELL BOEHNEN
HULBERT & BERGHOFF

Patrick G. Gattari
Reg. No. 39,682

McDONNELL BOEHNEN
HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this 4th day of February 2004.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-896-A

Serial No.

10/678,927

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Gould, et al

Filing Date:

October 3, 2003

Group:

1614



U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1	5,691,453	11/25/97	Wirtz, et al			
	2	5,084,558	01/28/92	Rausch, et al			
	3	5,890,852	11/28/98	Rausch, et al			
	4	5,955,581	09/21/98	Rausch, et al			
	5	5,691,452	11/25/97	Gawryl, et al			
	6	6,150,507	11/21/00	Houtchens, et al			
	7	5,895,810	04/20/99	Light, et al			
	8	6,271,351	08/07/01	Gawryl, et al			
	9	6,288,027	09/11/01	Gawryl, et al			
	10	4,826,811	05/23/89	Sehgal, et al			
	11	5,464,814	11/07/95	Sehgal, et al			
	12	6,498,141	12/24/02	DeWoskin, et al			
	13	2002/0065211	05/30/02	Jacobs, Jr., et al			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-896-A

Serial No.

10/678,927

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Gould, et al

Filing Date:

October 3, 2003

Group:

1614

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	14	Gould, S.A., et al., <i>The Life-Sustaining Capacity of Human Polymerized Hemoglobin when Red Cells Might Be Unavailable</i> , Journal of the American College of Surgeons, 195 (4): 445-455 (October, 2002).
	15	Carson, J.L., et al., <i>Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion</i> , Transfusion, 42: 812-818 (July, 2002).
	16	Moore, F.A., et al., <i>Trauma Resuscitation</i> , ACS Surgery- Principles & Practice, 31-61 (2002).
	17	American College of Surgeons Committee on Trauma. <i>Advanced Trauma Life Support Program for Physicians 1997 Instructional Manual</i> , 6 th , ed. Chicago: American College of Surgeons; 98-117 (1997).
	18	Farion, K.J., et al., <i>Changes in Red Cell Transfusion Practice among Adult Trauma Victims</i> , J. Trauma, 44(4):583-587 (1998).
	19	Baker, J.B., et al., <i>Type and Crossmatch of the Trauma Patient</i> , J. Trauma, 50(5):878-881 (May, 2001).
	20	DeFoe, G.R., et al., <i>Lowest Hematocrit on Bypass and Adverse Outcomes Associated with Coronary Artery Bypass Grafting</i> , Ann Thorac Surg., 71:769-776 (2001).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-896-A

Serial No.

10/678,927

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Gould, et al

Filing Date:

October 3, 2003

Group:

1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

21	Wu, W.C., <i>et al.</i> , <i>Blood Transfusion in Elderly Patients with Acute Myocardial Infarction</i> , New England Journal of Medicine, 345(17):1230-1236 (October, 2001).
22	Practice Guidelines for Blood Component Therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy, <i>Anesthesiology</i> 84(3):732-747 (March, 1996).
23	Consensus Conference. Perioperative Red Blood Cell Transfusion, <i>JAMA</i> 260(18): 2700-2703 (November, 1988)
24	Gould, S.A., <i>et al.</i> , <i>Fluosol DA-20 As A Red Cell Substitute in Acute Anemia</i> , New England Journal of Medicine, 314(26):1653-1656 (June, 1986).
25	Spence, R.K., <i>et al.</i> , <i>Fluosol DA-20 in the treatment of severe anemia: Randomized, controlled study of 46 patients</i> , <i>Critical Care Medicine</i> , 18(11):1227-1230 (November, 1990).
26	Spence, R.K., <i>et al.</i> , <i>Is Hemoglobin Level Alone a Reliable Predictor of Outcome in the Severely Anemic Patient?</i> <i>The American Surgeon</i> , 58(2):92-95 (1992).
27	Carson, J.L., <i>et al.</i> , <i>Severity of Anaemia and Operative Mortality and Morbidity</i> , <i>Lancet</i> 1(8588):727-729 (April, 1988).
28	Carson, J.L., <i>et al.</i> , <i>Effect of anaemia and cardiovascular disease on surgical mortality and morbidity</i> , <i>Lancet</i> , 348(9034):1055-1060 (October, 1996).
29	Viele, M.K., <i>et al.</i> , <i>What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses</i> , <i>Transfusion</i> 34(5):396-401 (1994).
30	Sehgal L.R., <i>et al.</i> , <i>Polymerized pyridoxylated hemoglobin: A red cell substitute with normal oxygen capacity</i> , <i>Surgery</i> 95:433-438 (1984).
31	Amberson, W.R., <i>et al.</i> , <i>Clinical Experience with Hemoglobin-Saline Solutions</i> , <i>J. Applied Physiology</i> , 1(7):469-489 (January, 1949).
32	Brandt, J.L., <i>et al.</i> , <i>The Effects of Hemoglobin Solutions on Renal Functions in Man</i> , <i>Blood</i> , 6:1152-1158 (1951).
33	Miller, J.H., <i>et al.</i> , <i>The Effect of Hemoglobin on Renal Function in The Human</i> , <i>Journal of Clinical Investigation</i> , 30:1033-1040 (July, 1951).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-896-A

Serial No.

10/678,927

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Gould, et al

Filing Date:

October 3, 2003

Group:

1614

34	Savitsky, J.P., <i>et al.</i> , <i>A clinical trial of stroma-free hemoglobin</i> , Clinical Pharmacology Journal, 23(1):73-80 (January, 1978).
35	Carmichael, F.J., <i>et al.</i> , <i>A phase I study of oxidized raffinose cross-linked human hemoglobin</i> , Crit Care Med, 28(7):2283-2292 (2000).
36	Kasper, S.M., <i>et al.</i> , <i>Effects of a Hemoglobin-Based Oxygen Carrier (HBOC-201) on Hemodynamics and Oxygen Transport in Patients Undergoing Preoperative Hemodilution for Elective Abdominal Aortic Surgery</i> , Anesth Analg, 83:921-927 (1996).
37	LaMuraglia, G.M., <i>et al.</i> , <i>The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution</i> , J. Vascular Surgery, 31(2):299-308 (February, 2000).
38	Sloan, E.P., <i>et al.</i> , <i>Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic Shock</i> , JAMA 282:1857-1864 (November, 1999).
39	Gould, S.A., <i>et al.</i> , <i>Clinical Utility of Human Polymerized Hemoglobin as a Blood Substitute after Acute Trauma and Urgent Surgery</i> , J. Trauma 43(2):325-332 (August, 1997).
40	Gould, S.A., <i>et al.</i> , <i>The First Randomized Trial of Human Polymerized Hemoglobin as a Blood Substitute in Acute Trauma and Emergent Surgery</i> , J Am Coll Surg 187(2):113-122 (August, 1998).
41	Vengelen-Tyler, V., American Association of Blood Banks Technical Manual. 13 th ed., Bethesda (MD): American Association of Blood Banks, p. 389-396 (1999).
42	Huston, P., <i>et al.</i> , <i>Withholding Proven Treatment in Clinical Research</i> , New England Journal of Medicine 345(12):912-914 (September, 2001).
43	Emanuel, E.J., <i>et al.</i> , <i>The Ethics of Placebo-Controlled Trials- A Middle Ground</i> , New England Journal of Medicine, 345(12):915-914 (September, 2001).
44	Carson, J.L., <i>et al.</i> , <i>Mortality and morbidity in patients with very low blood counts who decline blood transfusion</i> , Transfusion, 42:812-818 (July, 2002).
45	Reiner, A.P., <i>Massive Transfusion</i> , Perioperative Transfusion Medicine, p.351-364 (1998).
46	Weiskopf, R.B., <i>et al.</i> , <i>Human Cardiovascular and Metabolic Response to Acute, Severe Isovolemic anemia</i> , JAMA 279(3): 217-221 (January, 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


02-896-A

Serial No.

10/678,927

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Gould, et al

Filing Date:

October 3, 2003

Group:

1614

47	Wilkerson, D.K., <i>et al.</i> , <i>Limits of cardiac compensation in anemic baboons</i> , Surgery, 103(6):665-670 (1988).
48	Levy, P.S., <i>et al.</i> , <i>Oxygen Extraction Ratio: A Valid Indicator of Transfusion Need in a Limited Coronary Vascular Reserve?</i> J. Trauma 32(6):769-774 (June, 1992).
49	Schwartz, J.P., <i>et al.</i> , <i>The Influence of Coronary Stenosis On Transfusion Need.</i> , Cardiothoracic Surgery, Surgical Forum XLIV:226-228 (1993).
50	Moss, G.S., <i>et al.</i> , <i>Transport of Oxygen and Carbon Dioxide by Hemoglobin-Saline Solution in the Red Cell-Free Primate</i> , Surg. Gynecol Obstet, 142:357-362 (March, 1976).
51	Frantantoni, J.C., <i>Points to consider on efficiency evaluation of hemoglobin and perfluorocarbon based oxygen carriers</i> , Transfusion 34(8):712-713 (1994).
52	Frantantoni, J.C., <i>Red Cell Substitutes: Evolution of Approaches for Demonstrating Efficacy</i> , Blood-substitutes – Present and Future Perspectives, Elsevier Science S.A., p. 33-39 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.